The record
| Class | metallopeptide |
|---|---|
| Also known as | - |
| Chain length | - |
| Molecular weight | 403.92 Da |
| Half-life | 1 hour (rapid tissue uptake) |
| Route | - |
| Studied for | - |
| Research use | - |
| What has been shown | - |
| How it works | Collagen/elastin synthesis; Glycosaminoglycan synthesis; Anti-inflammatory; Antioxidant (SOD/catalase upregulation) |
| Patent status | - |
| Regulatory status | - |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Joint / Tendon Healing (affection, 53%)
- Muscle Recovery (affection, 66%)
- Wound Healing / Tissue Repair (affection, 60%)
- Skin Regeneration / Aesthetic Healing (affection, 70%)
- Nerve Support / Neuro-repair Environment (affection, 35%)
- GI Inflammation Modulation (affection, 36%)
- Neuroprotection Signaling (affection, 49%)
- Inflammation Modulation (affection, 56%)
- Oxidative Stress Resilience (affection, 39%)
- Bone Health / Remodeling Support (affection, 57%)
- Anti-fibrotic Signaling Environment (affection, 48%)
- Acetaminophen toxicity (illness, 30%)
- Androgenetic alopecia (illness, 60%)
- Antioxidant supplementation (illness, 30%)
- Cancer immunotherapy adjuvant (illness, 30%)
- Cardiac repair (illness, 30%)
- Corneal injuries/dry eye (illness, 30%)
- COVID-19 (illness, 30%)
- Detoxification support (illness, 30%)
- Duchenne muscular dystrophy (illness, 30%)
- Hair follicle regeneration (illness, 60%)
- Hepatitis B/C treatment (illness, 30%)
- Joint/cartilage repair (illness, 40%)
- Musculoskeletal system support (illness, 40%)
- Neuromuscular diseases (illness, 30%)
- Neurotrophic keratopathy (illness, 30%)
- Osteoarthritis (illness, 40%)
- Scar reduction (illness, 60%)
- Sepsis treatment (illness, 30%)
- Skin lightening (illness, 30%)
- Vaccine adjuvant (illness, 30%)
- Wound healing enhancement (illness, 60%)
- Pain (symptom, 50%)
- Joint pain or stiffness (symptom, 50%)
- Slow healing of an injury (symptom, 50%)
- Fatigue or low energy (symptom, 33%)
- Muscle loss or weakness (symptom, 33%)
- Skin ageing or thinning (symptom, 75%)
- Frequent infections (symptom, 50%)